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OBJECTIVES: Many key pharmaceutical markets (including England, Scotland, 
Canada and Australia) have Health Technology Assessment (HTA) bodies for which 
cost-utility analyses are key criteria. For such bodies, acceptable cost per Quality-
Added Life Year (QALY) based on the manufacturer’s submitted price must be dem-
onstrated. By contrast, in other major markets (such as France and Germany), a level 
of added benefit is ascribed to a drug and based upon this a price is negotiated. 
However, the expansion of international reference pricing means that prices in 
major ex-US markets are increasing converging. Thus the major difference between 
such agencies becomes the coverage, which this research compares, using the exam-
ple of 2 recent high cost breast cancer therapies. METHODS: Publically available HTA 
reports for Kadcyla and Perjeta from the pan-Canadian Oncology Review (pCODR), 
National Institute for Health and Care Excellence (NICE), Scottish Medicine Council 
(SMC), Institute for Quality and Efficiency in Healthcare (IQWiG, Germany), Haute 
Autorite de Sante (HAS, France), and Australian Pharmaceutical Benefits Advisory 
Committee (PBAC) were screened (up to December 2014) and the decision, date 
and key rationale were extracted. RESULTS: NICE, SMC, PBAC, and pCODR have all 
appraised both Kadcyla and Perjeta but none of these bodies have found either of 
these drugs to be cost-effective. By contrast, HAS and IQWiG have both appraised 
Kadcyla and Perjeta, granted coverage and found these to offer an added benefit 
compared to existing standard of care, thus securing it a negotiated premium over 
comparator therapies. CONCLUSIONS: Obligatory cost-utility bodies assess cost-
effectiveness based on the manufacturer’s price, which is often deemed not cost-
effective, resulting in frequent delays and denials to access of innovative products. 
However, if cost-utility bodies instead confidentially evaluated the QALY benefit and 
determined the proposed price based on this they could achieve potentially much 
better coverage without compromising their cost-utility principles.
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OBJECTIVES: Almost every Central Asian (CA) country, regulatory and reimburse-
ment authorities increasingly require pharmacoeconomic evaluation, as part of a 
formulary listing or reimbursement submission. A budget impact analysis (BIA) 
estimates fiscal consequences of adopting a new health technology or interven-
tion within a specific health context. Rapid benefit assessment (RBA) as a basis 
for central price regulation planned to introduce for new drugs in Kazakhstan. The 
objective was to investigate the converging trends in the BIA requirements in the 
CA countries and to compare them with the situation in Kazakhstan. METHODS: 
We conducted a survey of requirements for the pricing and reimbursement process 
of pharmaceuticals in 5 countries (Kazakhstan, Tajikistan, Kyrgyzstan, Uzbekistan, 
Turkmenistan). Where needed informal stakeholder interviews were used to sup-
plement lacking information. RESULTS: Increasing accessibility and affordability 
of healthcare services have been considered as important policy objectives in 
Kazakhstan. In the recent years, because a vast national drug formulary and state 
benefit outpatient drug program, there are problems with drug provision, cost of 
medical expenditure is rapidly growing and becoming increasingly unaffordable. 
Opportunities in all CA countries result from increasing affluence and life expec-
tancy and the diseases associated with these. Some challenges to market access 
are: poor IP protection, protectionist measures, compulsory licensing, drive to use 
generics or biosimilars, often produced locally, price controls, variable health insur-
ance/NHS coverage, and limited budgets for prescription drugs. Although demand 
for new drugs is increasing in these markets, protectionism measures, competition 
from generics and budget constraints due to the increased burden and requirement 
for new high priced drugs present a challenge when accessing the pharmaceutical 
market in CA countries. CONCLUSIONS: All of the investigated countries request no 
BIA from a payers perspective the drugs impact on the change in medical resource 
consumption is analyzed as part of the pharmacoeconomic and comparative effec-
tiveness analyses.
HealTH care use & Policy sTudies – Health care research & education
PHP120
gender differences in THe use of comPlemenTary and alTernaTive 
medicine among adulTs wiTH mulTiPle cHronic condiTions
Alwhaibi M., Sambamoorthi U.
West Virginia University, Morgantown, WV, USA
OBJECTIVES: To examine the association between gender and CAM use among adults 
with multiple chronic conditions (MCC). METHODS: This study used a cross-sectional 
design with data from 2012 National Health Interview Survey. CAM use was meas-
ured using 18 variables. Type of CAM use consisted of alternative medical systems, 
mind-body therapy, and manipulative-body-based therapy. The relationships between 
gender and CAM use and types of CAM use were assessed with chi-square tests 
and logistic and multinomial logistic regressions. Separate logistic regression and 
multinomial logistic regressions among women and men were performed to assess 
the factors that are associated with CAM use in each group. RESULTS: Overall, 51.5% 
women and 44.3% men reported ever using CAM; in the past 12 months, 27.6% women 
and 18.9% men used CAM. Across all types of CAM, higher percentages of women 
than men used CAM. After controlling for demographic, socio-economic, health and 
lifestyle factors, women were more likely to report ever using CAM (AOR= 1.49; 95% 
CI [1.35, 1.65]) compared to men. Separate multinomial regressions of CAM use in the 
past 12 months revealed that the factors associated with CAM use were different for 
men and women. Women with both physical and mental health conditions were more 
likely to use CAM in the past 12 months (AOR= 1.38; 95% CI [1.17, 1.64]) compared to 
those with only physical conditions; but no such relationship was found in men. The 
relationship between age and type of CAM use was significant for women and not 
for men. CONCLUSIONS: Among individuals with MCC, women were more likely to 
purpose. METHODS: An electronic quantitative survey was administered to 150 
attendees of the 17th ISPOR European Congress in Amsterdam, Netherlands, in 
November 2013, using a random sampling method. The respondents included 
representatives from academia, industry, consulting firms, clinicians, and public/
government agencies. RESULTS: Respondents identified the five most important 
attributes driving positive reimbursement as: cost-effectiveness, quality of life, clini-
cal efficacy, budget impact, and therapeutic innovativeness. Almost all respondents 
(91.3%) believe ICER thresholds should be used to evaluate new health technolo-
gies (formally or informally). Approximately 75.9% believe that ICER thresholds 
should increase beyond the current value of £30,000/QALY. The average suggested 
threshold is £51,274/QALY, regardless of therapeutic area. For a disease with high 
clinical unmet need, respondents suggest an average threshold of £61,535/QALY. 
The majority of respondents believe ICER thresholds should be an integral part of 
HTA; however, many believe the current thresholds inadequately reflect the value of 
innovative therapies. Specifically, respondents expressed that the thresholds should 
be raised for innovative treatments in therapeutic areas lacking significant treat-
ment alternatives, as well as novel treatments for rare diseases. Additionally, 69.0% 
of respondents believe that the current level of ICER thresholds limits the availability 
of truly innovative therapies; hence a new threshold that varies by therapeutic area 
and degree of clinical unmet need should be established. CONCLUSIONS: A major-
ity of respondents support the use of health economic evaluation, but believe that 
current ICER thresholds are too low and do not accurately reflect the value of novel 
therapies. The average threshold suggested is £51,274/QALY. Respondents indicate 
that the current ICER thresholds limit patient access to truly innovative therapies.
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OBJECTIVES: The objective of this study was to identify recently launched molecules 
in Japan that were priced using the cost-plus calculation vs. cost-comparison pricing 
method and to evaluate the rationale behind their pricing decisions. METHODS: 
211 molecules assessed for pricing between March 2011 and August 2014 in Japan by 
the Ministry of Health, Labour and Welfare (MHLW) were considered in this analy-
sis. RESULTS: Of 211 molecules assessed for pricing between March 2011 and August 
2014, 71 (34%) molecules had a novel mechanism of action for their respective 
indication, while 140 (66%) did not. Of the 71 novel mechanism of action molecules, 
53 (75%) molecules underwent cost-plus pricing, while 18 (25%) underwent cost-
comparison pricing. 15 of the 18 likely underwent cost-comparison pricing either 
due to their non-differentiated clinical efficacy or similar mechanism of action 
as those of existing molecules or due to the crowdedness of the space; 3 of the 
18 underwent cost-comparison pricing due to their mechanisms of action being 
broadly defined. Of the 140 non-novel molecules, only 7 (5%) molecules were priced 
under cost-plus pricing despite not being first in class, as their comparators had 
launched 15+ years ago and were thereby deemed inappropriate for comparison 
purposes. CONCLUSIONS: The majority of novel mechanism of action molecules 
underwent cost-plus pricing. Nevertheless, a number of molecules with novel mech-
anisms of action were priced under cost-comparison pricing. Conversely, several 
non-novel molecules were priced under cost-plus pricing despite not being first in 
class. It can therefore be concluded that while the novelty of a molecule’s mecha-
nism of action serves as the main driver for determining which pricing method is 
used by the MHLW, it is not the only driver behind the decision.
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OBJECTIVES: In several countries, incremental cost-effectiveness ratio (ICER) 
“thresholds” aid in the healthcare decision-making process by helping prioritize 
the distribution of resources across interventions. The aim of the study was to 
assess the use of ICER thresholds in the P&R process, and understand the evolution 
of ICER thresholds over time. METHODS: A targeted literature review was conducted 
using search terms to address the following research questions: (i) How have ICER 
thresholds changed over time to reflect advances in medical technology? (ii) What 
is the societal willingness to pay (WTP) per QALY? (iii) How do the ICER values of 
interventions treating different diseases compare? PubMed and Grey Literature 
were searched for relevant studies published in English between January 1970 and 
September 2014. RESULTS: This review summarizes evidence from 48 studies. 
Literature revealed that countries use explicit and implicit ICER thresholds during 
the P&R process. In the US and UK, thresholds were established in 1982 and 1999 
respectively, and despite significant advances in medical technology, these have 
not been updated. Our review indicates that the estimated societal WTP in the US 
is between $109,000–$297,000/QALY, and it has been recommended that the ICER 
threshold be raised to at least $200,000/QALY. Additionally, our review shows that 
ICER values vary significantly for different therapeutic areas based on medication 
cost, unmet need, and severity. For example, the average ICER value for an interven-
tion treating Non-Small Cell Lung Cancer ($100,442/QALY) is approximately four-fold 
that of Type 2 Diabetes ($22,663/QALY). CONCLUSIONS: Researchers cite that ICER 
thresholds are dynamic, and should change over time to account for innovation in 
technology, inflation and increased research and development costs. In addition to 
end-of-life care, efforts should be made to establish different thresholds for diseases 
with high unmet needs to facilitate patient access to novel therapies.
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